Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

Anti-Cancer Drugs

Volumn 13, Issue 7, 2002, Pages 767-775

  Loos, Walter J ^a   Szebeni, Janos ^a   Ten Tije, Albert J ^a   Verweij, Jaap ^a   Van Zomeren, Desirée M ^a   Chung, Kyu Nung ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cremophor EL; Drug delivery vehicle; Paclitaxel; Solubilizer

Indexed keywords

ACEPOROL 345 T; ACEPOROL 460; CREMOPHOR; DRUG VEHICLE; ESTERASE; PACLITAXEL; POLYSORBATE 80; RICIPOROL 335; SOLUBILIZER; SORPOROL 120EX; SORPOROL 230; ANTINEOPLASTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ARTICLE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME DEGRADATION; EQUILIBRIUM DIALYSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; PRIORITY JOURNAL; BLOOD; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; SOLUBILITY; SOLUTION AND SOLUBILITY; STANDARD; VEHICLES;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMAN; IN VITRO; INDICATORS AND REAGENTS; PACLITAXEL; PHARMACEUTICAL SOLUTIONS; REFERENCE STANDARDS; SOLUBILITY; VEHICLES; HUMANS;

EID: 0036667948     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200208000-00012     Document Type: Article

References (21)

1. Taxol: A history of pharmaceutical development and current pharmaceutical concerns
2. Pharmacology and toxicology of Cremophor EL diluent
3. Overview of taxol safety
4. Hypersensitivity reactions from taxol
5. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
6. Formation of complement-activating particles in aqueous solution of Taxol: Possible role in hypersensitivity reactions
7. Pharmacokinetics of the taxanes
8. Role of formulation vehicles in taxane pharmacology
9. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
10. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
11. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles
12. Progress in the development of alternative pharmaceutical formulations of taxanes
13. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
14. Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
15. Determination of total topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography
16. Measurement of fraction unbound paclitaxel in human plasma
17. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
18. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
19. Phase I and pharmacological study of CT-2103, a poly(l-glutamic acid)-paclitaxel conjugate
20. Disposition of Taxoprexin® DHA-paclitaxel (TXP), a novel taxane, in blood: In vitro and clinical pharmacokinetic (PK) studies
21. Preliminary report of a phase I study of escalating dose PG-Paclitaxel (CT-2103) and fixed dose cisplatin in patients with various solid tumors